An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exicure, Inc. received a Nasdaq Delinquency Notice for failing to timely file its Annual Report on Form 10-K, leading to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company must submit an updated plan to regain compliance by May 20, 2024.
Exicure, Inc. ha ricevuto un Avviso di Inadempienza da Nasdaq per non aver presentato tempestivamente il suo Rapporto Annuale sul modulo 10-K, risultando non conforme alla Regola di Quotazione Nasdaq 5250(c)(1). L'azienda deve presentare un piano aggiornato per riacquisire la conformità entro il 20 maggio 2024.
Exicure, Inc. recibió una Notificación de Incumplimiento de Nasdaq por no presentar su Informe Anual en el Formulario 10-K a tiempo, lo que llevó a un incumplimiento de la Norma de Listado Nasdaq 5250(c)(1). La compañía debe enviar un plan actualizado para recuperar el cumplimiento antes del 20 de mayo de 2024.
Exicure, Inc.는 연례 보고서(Form 10-K)를 제때 제출하지 못하여 나스닥 상장 규칙 5250(c)(1)을 준수하지 못했다는 통지를 받았습니다. 회사는 2024년 5월 20일까지 준수 상태를 회복하기 위한 업데이트된 계획을 제출해야 합니다.
Exicure, Inc. a reçu un avis de non-conformité de Nasdaq pour ne pas avoir déposé à temps son rapport annuel sur le formulaire 10-K, entraînant une non-conformité avec la Règle de Cotation Nasdaq 5250(c)(1). La société doit soumettre un plan mis à jour pour retrouver la conformité avant le 20 mai 2024.
Exicure, Inc. hat eine Mängelanzeige von Nasdaq erhalten, da es seinen Jahresbericht auf Formular 10-K nicht rechtzeitig eingereicht hat und damit gegen die Nasdaq Listing Regel 5250(c)(1) verstoßen hat. Das Unternehmen muss bis zum 20. Mai 2024 einen aktualisierten Plan zur Wiedererlangung der Konformität vorlegen.
Positive
None.
Negative
None.
The notification of non-compliance that Exicure, Inc. has received from Nasdaq is a red flag for investors as it signifies potential issues within the company's internal controls or external factors impacting their reporting. Delays in filing mandatory financial reports could indicate deeper financial troubles or perhaps a strategic reevaluation that has caused a workflow backlog. Investors should closely monitor the situation as the company's ability to meet the extended deadline of May 20, 2024, for its Form 10-Q and the soon-to-be-filed Form 10-K will be telling of its operational efficiency and financial health. A failure to meet this deadline could lead to further sanctions from Nasdaq, such as a trading halt or delisting, which would considerably affect the stock's liquidity and investor sentiment.
From a regulatory standpoint, Exicure's delay in filing its annual report raises concerns about its adherence to the Sarbanes-Oxley Act, which mandates strict reforms to improve financial disclosures from corporations and prevent accounting fraud. Non-compliance with such regulations can not only lead to punitive measures from the exchange but also undermine investor confidence. If the company corrects the filing delinquency within the provided grace period, it may avoid severe consequences. However, investors should evaluate the implications of this notice on the company's reputation and the management's ability to uphold corporate governance standards.
It's essential to consider the broader market and industry implications of Exicure's filing delay. If the reason behind the postponement is unique to the company, the impact may be limited to its stock. However, if this is indicative of a trend among peers, such as supply chain issues, regulatory challenges, or sector-wide financial constraints, it could foreshadow similar announcements from other companies within the industry, potentially affecting sector indices and investor outlook. Additionally, given that Exicure is a biotech firm, this delay could also signal a shift in research and development priorities or funding allocation. Stakeholders should thus keep an eye on industry trends for a comprehensive evaluation.
CHICAGO--(BUSINESS WIRE)--
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).
The Letter states that the Company must submit an update to its original plan to regain compliance with respect to the filing requirements. The plan initially related to the Company’s delinquency in filing its Form 10-Q for the quarter ended September 30, 2023, and the Nasdaq staff granted an exception giving the Company until May 20, 2024 to file the third quarter Form 10-Q. Any additional exceptions to allow the Company to regain compliance with all delinquent filings (both the third quarter Form 10-Q and the Form 10-K) will be limited to May 20, 2024.
The Company is working diligently to complete its Form 10-K and intends to file the Form 10-K as soon as practicable to regain compliance with the Rule.
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company’s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “advance,” “believes,” “target,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 27, 2023, as updated by the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
